



bi-scaffold
International

61 Science Park Road,
#02-01/06, The Galen,
Singapore Science Park II,
Singapore 117525.

Tel: (+65) 6465 5395

Fax: (+65) 6465 5394

Website: www.bio-scaffold.com

General Enquiries: enquiry@bio-scaffold.com

Human Resources: recruit@bio-scaffold.com

Sales & Marketing: salesandmarketing@bio-scaffold.com

Distributor: distributor@bio-scaffold.com

CORPORATE PROFILE



■ COMPANY HISTORY

Founded in 1999, Bio-Scaffold International Pte Ltd ("BSI" or the "Company") initiated R&D efforts in collaboration with SIMTech on the technology development for scaffolds to be applied in Guided Tissue Engineering. Funded by Spring Singapore under the Local Enterprise Technical Assistance Scheme, the partnership produced a revolutionary technology for bio-scaffold processing and the breakthrough prototype was ready in December 2003. A joint patent with A*STAR was subsequently filed and porous bio-scaffolds ("Bioscaff") were developed using the technology. The scaffolds produced using the cutting edge technology passed the preliminary in-vitro and in-vivo tests in August 2005 and later in March 2006. These tests were conducted by the Faculty of Dentistry at the National University of Singapore (NUS) under the umbrella of TEC grant sponsored by Prime Minister's Office. The scaffolds were subsequently tested for clinical effectiveness using human trials.

■ GRANTS & AWARDS

- The Enterprise Challenge Grant (TEC) sponsored by the Prime Minister's Office (2005)
- The Enterprise Challenge Innovator Award, together with the Faculty of Dentistry from the National University of Singapore
- Professional Enterprise (Prestige) Award in citation from Asian Management Association (2007)
- FDI World Dental Congress (Poster Presentation Award) (2009)

■ OUR UNIQUE TECHNOLOGY

Our revolutionary patented technology creates tremendous potential for the production of customized scaffolds for various applications using biocompatible materials for human tissue, bone, joint and ligament regeneration.

BSI's first line of product, Bioscaff™ Alvelac™, is a porous, synthetic scaffold, developed and manufactured from FDA-approved synthetic biopolymer PLGA. It is designed with macro channels and micropores to provide maximum space while preventing the bone walls from collapsing for natural healing and facilitate the growth of new bone. Bioscaff™ Alvelac™ will thereafter degrade and metabolise in the body into lactic acid and glycolic acid, which are metabolised further and excreted as carbon dioxide and water. This process typically occurs over a time frame of approximately two to six months.

■ OUR PRODUCT – THE FUTURE OF TISSUE REGENERATION

Since early 2009, having completed multi-centre clinical trials, Bioscaff™ Alvelac™ is successfully test marketed as a scaffold for alveolar socket preservation in dentistry. We are working on extending the application beyond dentistry to other medical segments such as cosmetic and orthopaedic surgery using our current technology.

■ ON THE HORIZON

In tandem, the Company is expanding its geographical footprint overseas to seize the opportunities presented by capitalizing on its strong reputational image as a Singaporean brand. In Asia, BSI is working closely with various dental communities to drive awareness and support of its products. It has ongoing research partnership with various dental institutions that will entrench the company's position within the radar of young emerging dentists. This is also aligned with the Company's objectives to target the next generation of users who will find familiarity within the applications of biotechnology and its function in dental lifestyle.

COMPANY



Cert No.: 2008-1-0843
ISO 9001



Cert No.: Q1N 07 10 63748 001
ISO 13485



Professional Enterprise
(Prestige) Award



Professional Enterprise
(Significance in Business
Scalability) Award

ALVELAC™



HSA Product Registration:
(Reg. No.: DE0004718)